BOTZ vs IBB
Global X Robotics & Artificial Intelligence ETF vs iShares Biotechnology ETF
- • IBB has the lower expense ratio at 0.44% vs 0.68% for BOTZ.
- • BOTZ pays a higher dividend yield (0.54%).
Side-by-side metrics
| Metric | BOTZ | IBB |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.68% | 0.44% |
Dividend yield Trailing 12-month yield. | 0.54% | 0.16% |
AUM Assets under management — bigger funds are typically more liquid. | $3.04B | $11.50B |
YTD return | -11.96% | 30.22% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.86 | 0.60 |
P/E ratio | 35.20 | 25.48 |
Last price | $32.39 | $217.75 |
Inception | — | — |
Issuer | Global X | iShares |
BOTZ top holdings
| ISRG | Intuitive Surgical Inc | 9.94% |
| 6861.T | Keyence Corp | 8.65% |
| 6954.T | Fanuc Corp | 8.59% |
| NVDA | NVIDIA Corp | 7.81% |
| ABBN.SW | ABB Ltd | 7.71% |
| 6273.T | SMC Corp | 4.67% |
| 6383.T | Daifuku Co Ltd | 3.43% |
| 300124.SZ | Shenzhen Inovance Technology Co Ltd Class A | 2.93% |
| CGNX | Cognex Corp | 2.60% |
| TSLA | Tesla Inc | 2.40% |
IBB top holdings
| GILD | Gilead Sciences Inc | 8.94% |
| AMGN | Amgen Inc | 8.31% |
| VRTX | Vertex Pharmaceuticals Inc | 7.87% |
| REGN | Regeneron Pharmaceuticals Inc | 6.24% |
| MRNA | Moderna Inc | 5.49% |
| NTRA | Natera Inc | 3.78% |
| ARGX | argenx SE ADR | 3.36% |
| BIIB | Biogen Inc | 2.52% |
| RVMD | Revolution Medicines Inc Ordinary Shares | 2.50% |
| ILMN | Illumina Inc | 2.41% |
About BOTZ
BOTZ (Global X Robotics & Artificial Intelligence ETF) is Robotics, automation, and AI companies globally. Managed by Global X, the fund carries $3.0B in assets under management, an expense ratio of 0.68%, a dividend yield of 0.54%. Its largest holding is Intuitive Surgical Inc (ISRG), which represents 9.9% of the portfolio. Consumer Cyclical is the fund's largest sector exposure at 5.7%.
About IBB
IBB (iShares Biotechnology ETF) is NASDAQ biotech and pharmaceutical companies. Managed by iShares, the fund carries $11.5B in assets under management, an expense ratio of 0.44%, a dividend yield of 0.16%. Its largest holding is Gilead Sciences Inc (GILD), which represents 8.9% of the portfolio. Healthcare is the fund's largest sector exposure at 100.0%.